Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07199309 · ClinicalTrials.gov registry record · Phase 2
A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
A Phase 2 study of Hypertriglyceridemia, sponsored by Marea Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07199309: Recruiting Phase 2 study of Hypertriglyceridemia, sponsored by Marea Therapeutics.
NCT07199309 is a Phase 2 study of Hypertriglyceridemia that is actively recruiting participants, run by Marea Therapeutics. The registered enrollment target is 30 participants, below the 175-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07199309, a Phase 2 study of Hypertriglyceridemia, is actively recruiting participants, sponsored by Marea Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of the study is to determine the effect of MAR001 as compared to placebo on levels of the triglycerides (TG) in the postprandial state in adults with elevated TG.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MAR001
Study Locations (1)
California
- Marea Site 301 - Chula Vista
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-09-26 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
What NCT07199309 shows while recruiting
NCT07199309 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 175-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07199309 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07199309 about?
NCT07199309 is a clinical study titled "A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol". The primary objective of the study is to determine the effect of MAR001 as compared to placebo on levels of the triglycerides (TG) in the postprandial state in adults with elevated TG.
What is the current status of trial NCT07199309?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-09-26. Estimated completion is 2026-11.
What conditions does trial NCT07199309 study?
This clinical trial studies the following conditions: Hypertriglyceridemia.
What interventions are being tested in trial NCT07199309?
The interventions under investigation include: Placebo (DRUG), MAR001 (DRUG).
Who is sponsoring clinical trial NCT07199309?
This trial is sponsored by Marea Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07199309 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertriglyceridemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07199309's enrollment target sits among peer trials
30 18th of 25 higher than 7 of 25 other Hypertriglyceridemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertriglyceridemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
ACTIVE NOT RECRUITING · Phase 2
-
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 2
-
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
COMPLETED · Phase 2
-
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
COMPLETED · Phase 2
-
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
RECRUITING · Phase 3
-
Differential Thrombogenesis by EPA and DHA Mediated by HDL
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI